- Home
- CPAY vs BIIB Comparison
CPAY vs BIIB Comparison
Compare CPAY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAY
- BIIB
- Stock Information
- Founded
- CPAY 1986
- BIIB 1978
- Country
- CPAY United States
- BIIB United States
- Employees
- CPAY N/A
- BIIB N/A
- Industry
- CPAY EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CPAY Technology
- BIIB Health Care
- Exchange
- CPAY Nasdaq
- BIIB Nasdaq
- Market Cap
- CPAY 24.6B
- BIIB 18.8B
- IPO Year
- CPAY 2010
- BIIB 1991
- Fundamental
- Price
- CPAY $333.07
- BIIB $135.28
- Analyst Decision
- CPAY Buy
- BIIB Buy
- Analyst Count
- CPAY 14
- BIIB 27
- Target Price
- CPAY $397.17
- BIIB $188.17
- AVG Volume (30 Days)
- CPAY 502.3K
- BIIB 1.2M
- Earning Date
- CPAY 08-06-2025
- BIIB 07-31-2025
- Dividend Yield
- CPAY N/A
- BIIB N/A
- EPS Growth
- CPAY 6.08
- BIIB 26.39
- EPS
- CPAY 14.26
- BIIB 10.12
- Revenue
- CPAY $4,045,005,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- CPAY $13.37
- BIIB N/A
- Revenue Next Year
- CPAY $10.56
- BIIB N/A
- P/E Ratio
- CPAY $23.29
- BIIB $13.29
- Revenue Growth
- CPAY 6.68
- BIIB 1.59
- 52 Week Low
- CPAY $265.06
- BIIB $110.04
- 52 Week High
- CPAY $400.81
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- CPAY 51.14
- BIIB 61.69
- Support Level
- CPAY $329.94
- BIIB $129.08
- Resistance Level
- CPAY $342.07
- BIIB $134.75
- Average True Range (ATR)
- CPAY 8.13
- BIIB 3.74
- MACD
- CPAY 0.60
- BIIB 0.65
- Stochastic Oscillator
- CPAY 67.66
- BIIB 82.50
About CPAY Corpay Inc.
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.